Compare DSX & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSX | ZURA |
|---|---|---|
| Founded | 1999 | 2022 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.0M | 252.9M |
| IPO Year | 2005 | N/A |
| Metric | DSX | ZURA |
|---|---|---|
| Price | $2.42 | $6.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 650.4K | ★ 830.1K |
| Earning Date | 02-26-2026 | 03-24-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 231.99 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $218,560,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.40 | N/A |
| P/E Ratio | $15.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $0.97 |
| 52 Week High | $2.39 | $6.88 |
| Indicator | DSX | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 69.07 | 58.88 |
| Support Level | $2.17 | $5.59 |
| Resistance Level | $2.33 | $6.88 |
| Average True Range (ATR) | 0.10 | 0.53 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 95.32 | 57.75 |
Diana Shipping Inc provides shipping transportation services. The company, through its subsidiaries, operates a fleet of vessels consisting of dry bulk carriers such as Panamax, Kamsarmax, Post-Panamax, Capesize and Newcastlemax vessels. Using this fleet, the firm provides transportation services for various goods including coal, iron ore, and grains. It also transports minor bulks, including steel products, cement, and fertilizers through its dry bulk carrier vessels. The operation of the vessels is the main source of revenue generation, the services provided by the vessels are similar and all operate under the same economic environment.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.